Life after death: targeting high mobility group box 1 in emergent cancer therapies.
about
Oncolytic viruses as therapeutic cancer vaccinesRadio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical ApplicationsConcepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapiesComplementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancerHMGB1 promotes a p38MAPK associated non-infectious inflammatory response pathway in human fetal membranes.Upregulation of heat shock proteins and the promotion of damage-associated molecular pattern signals in a colorectal cancer model by modulated electrohyperthermia.Association of Upregulated HMGB1 and c-IAP2 Proteins With Hepatocellular Carcinoma Development and Progression.Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy.Down-regulation of HMGB1 expression by shRNA constructs inhibits the bioactivity of urothelial carcinoma cell lines via the NF-κB pathwayHMGB1 silence could promote MCF-7 cell apoptosis and inhibit invasion and metastasis.IL-1β, RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies.Sulindac activates NF-κB signaling in colon cancer cells.Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia.Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity.Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses.Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies: a systematic review.The dual role and therapeutic potential of high-mobility group box 1 in cancer.Prognostic value of the high-mobility group box-1 in young patients with chest pain.Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer.The extracellular role of DNA damage repair protein APE1 in regulation of IL-6 expression.Overexpression of high mobility group box 1 contributes to progressive clinicopathological features and poor prognosis of human bladder urothelial carcinoma.Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy.Regulation of Tumor Progression by Programmed Necrosis.
P2860
Q21245758-7B8F087F-C13E-49EC-B96D-1AF36BDD8728Q26779221-71553F22-8393-4B61-B81F-C30A7614E17AQ26781215-4723C521-C308-4B63-BF07-B4DDE1384F41Q33602876-8DBEF536-1D22-41BA-8C5E-278370CF9EA5Q34626420-FF63A959-53A8-4499-94A7-206F2D3D20DDQ34628990-69184B84-2707-4D97-8F3F-C4157DAE9BDBQ35025037-ACCBF583-C113-4C0E-B936-DCEB03B3A14AQ35506253-9A207309-7C59-462A-B21B-93261D78C1FCQ35913266-0136D0F4-73BD-4321-8080-0FE3E0DCA039Q36511773-302C599C-406A-4C62-B5F9-8AF753E2E284Q37305013-28EA56E4-489B-4CCD-A60F-0EE5C4FE41A1Q37497981-0E55E830-1386-4891-A9DA-DA110AF8210EQ37636979-6365A438-2032-4E77-BBDF-61E3B9657B62Q37707676-B3D0ED8E-980B-47A5-BCC6-4111965B70F5Q38241666-7732C3EC-0887-4DFE-8533-0DD59DB0BE69Q38648891-85192BE7-EDDF-43B3-A54A-2061A7A07C3AQ39151877-54DFB818-F75A-4455-B1AD-A1227D768D61Q42362799-999D722E-E03E-46EA-AA66-468EE3F3F535Q42840421-EF2D3017-15EB-47A6-BDD8-D3286E4EC80AQ46090703-A5D99E96-67E8-45C5-A1B6-4FCF93C1EBFAQ48019408-07BB4578-6AE0-440E-910A-0A094A5CA8FBQ52562715-923FD98B-9D6A-43C9-913A-537401D474DEQ52581847-C21C37C5-8B36-4259-ADFB-3EBCCE8BD942Q52720171-BE1A16A7-B11E-4F3A-A5B7-06D1A5DB277C
P2860
Life after death: targeting high mobility group box 1 in emergent cancer therapies.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Life after death: targeting high mobility group box 1 in emergent cancer therapies.
@ast
Life after death: targeting high mobility group box 1 in emergent cancer therapies.
@en
type
label
Life after death: targeting high mobility group box 1 in emergent cancer therapies.
@ast
Life after death: targeting high mobility group box 1 in emergent cancer therapies.
@en
prefLabel
Life after death: targeting high mobility group box 1 in emergent cancer therapies.
@ast
Life after death: targeting high mobility group box 1 in emergent cancer therapies.
@en
P2093
P2860
P1476
Life after death: targeting high mobility group box 1 in emergent cancer therapies.
@en
P2093
Daolin Tang
David L Bartlett
Michael T Lotze
Z Sheng Guo
Zuqiang Liu
P2860
P577
2013-01-18T00:00:00Z